QIANJIANG YONGAN PHARMACEUTICAL CO., LTD.

Qianjiang Yongan Pharmaceutical Co., Ltd.

002365

CNE100000LZ9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 07/06/2024 am IST			5-day change	1st Jan Change
7.27 ^CNY	+2.97%		-7.03%	-25.66%

29/04	Qianjiang Yongan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 80 million worth of its shares.	CI
29/04	Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Qianjiang Yongan Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2022

March 31, 2023 at 01:48 am IST

Qianjiang Yongan Pharmaceutical Co., Ltd. announced on 30 March 2023 the final profit distribution proposal for 2022 of CNY 1.0000000 per ten shares (tax included).

Latest news about Qianjiang Yongan Pharmaceutical Co., Ltd.

Qianjiang Yongan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 80 million worth of its shares.	29/04	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	29/04	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	18/04	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/23/26	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23/23/23	CI
Qianjiang Yongan Pharma Patents Purification Method For Taurine Mother Liquor in Europe, Indonesia	09/23/09	MT
Qianjiang Yongan Pharmaceutical Co., Ltd Approves Cash Dividend for the Year 2022, Payable on July 5, 2023	22/23/22	CI
Yongan Pharma Registers New Health Food Products	06/23/06	MT
Qianjiang Yongan Pharma to Buy 6.5% Stake in Local Chemical Producer For 30 Million Yuan	24/23/24	MT
Huanggang Yongan Pharmaceutical Co., Ltd. announced that it expects to receive CNY 30 million in funding from Qianjiang Yongan Pharmaceutical Co., Ltd.	23/23/23	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2022	31/23/31	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	29/23/29	CI
Yongan Pharma Unit Gets Food Registration Certificate for Ginseng Tablets	06/23/06	MT
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/22/25	CI
Qianjiang Yongan Pharma Patents Taurine, Salt Preparation in Japan	11/22/11	MT
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/22/26	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	24/22/24	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/21/26	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	27/21/27	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Announces Final Cash Dividend for 2020, Payable on July 9, 2021	06/21/06	CI
Yongan Pharmaceutical Approves Final Cash Dividend for the Year 2020	30/21/30	CI
Wuhan Low-dimensional Materials Research Institute Co., Ltd. announced that it has received CNY 10 million in funding from Qianjiang Yongan Pharmaceutical Co., Ltd.	10/21/10	CI

Chart Qianjiang Yongan Pharmaceutical Co., Ltd.

Duration

Period

Chart Qianjiang Yongan Pharmaceutical Co., Ltd.

More charts

Qianjiang Yongan Pharmaceutical Co., Ltd. is a China-based company principally engaged in the manufacture and sales of taurine products. The Company operates through three main segments. The Taurine Products segment is mainly engaged in the research, development, manufacture and sales of taurine products, as well as the manufacture and sales of ethylene oxide. The Food Supplement segment is mainly involved in the research, development, manufacture and sales of dietary supplement, as well as the import and sales of overseas dietary supplement. The Health Field segment is mainly involved in the equity or industrial investment in health-related field.

Sector

Pharmaceuticals

Calendar

21/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
QIANJIANG YONGAN PHARMACEUTICAL CO., LTD.	-25.66%	30Cr
ELI LILLY AND COMPANY	+45.82%	77TCr
NOVO NORDISK A/S	+40.95%	63TCr
JOHNSON & JOHNSON	-6.16%	35TCr
MERCK & CO., INC.	+19.86%	33TCr
ABBVIE INC.	+9.32%	30TCr
ASTRAZENECA PLC	+18.45%	25TCr
ROCHE HOLDING AG	-0.78%	22TCr
NOVARTIS AG	+11.88%	22TCr
AMGEN INC.	+5.90%	16TCr

Other Pharmaceuticals